Aditxt Appoints Anthony Voorhies as Head of Business Development for AditxtScore™
November 20 2020 - 8:00AM
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that it has appointed Anthony Voorhies as Head of
Business Development for AditxtScore™.
Mr. Voorhies has commercialized a broad range of
diagnostic tools, biomarkers, and FDA-cleared imaging and
functional testing medical devices and has collaborated with some
of the world’s preeminent research institutions, conducting
training for research protocols and introducing complementary
diagnostics into clinical care models. He has spent over a decade
building and managing high performance teams in the health sciences
industry, growing them from early stage to high-growth performance.
Prior to joining Aditxt, Anthony helped deploy medical device,
diagnostics, and COVID-19 strategies for Calroy Health Sciences
LLC, and previously was the U.S. Product Director for Itamar
Medical, Inc.
Amro Albanna, Co-Founder and CEO of Aditxt,
commented, “AditxtScore is well-positioned for growth and Anthony
is the right leader to move the opportunity forward. He has the
extensive business and industry background that’s needed to launch
and grow the AditxtScore™ platform as an immune monitoring service
and shares our vision for the platform’s potential to transform
immune diagnosis from reactive testing to proactive monitoring. We
welcome him to our Aditxt family and look forward to realizing that
vision together.”
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Forward looking statements include
statements regarding the Company’s intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company’s ongoing and planned product
development; the Company’s intellectual property position; the
Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Company’s
prospectus, dated September 1, 2020, that was filed with the
Securities and Exchange Commission under File No. 333-248491, as
well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations: PCG Advisory Jeff Ramson Chief
Executive Officer IR@aditxt.com 646-762-4518 www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Oct 2023 to Oct 2024